Remove topic
article thumbnail

With global expansion planned, Krystal lays out blockbuster ambitions for topical gene therapy

Fierce Pharma

Not even one year after becoming a commercial biotech, Krystal Biotech has blockbuster dreams for its flagship product. | In its first six months of commercial availability, Krystal's topical gene therapy Vyjuvek raked in more than $50 million.

308
308
article thumbnail

Executive Interviews at Digital Pharma East 2023

Fierce Pharma

Fierce Pharma sits down with digital marketing leaders to discuss this year's most innovative topics at Digital Pharma East. Fierce Pharma sits down with digital marketing leaders to discuss this year's most innovative topics at Digital Pharma East. Learn more by watching the videos below.

Pharma 245
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Krystal's Vyjuvek becomes first topical gene therapy with FDA nod to treat rare skin disease

Fierce Pharma

Krystal's Vyjuvek becomes first topical gene therapy with FDA nod to treat rare skin disease zbecker Fri, 05/19/2023 - 16:25

FDA 363
article thumbnail

Leo Pharma's topical JAK drug posts phase 3 win in chronic hand eczema

Fierce Pharma

Leo Pharma's topical JAK drug posts phase 3 win in chronic hand eczema zbecker Mon, 02/13/2023 - 12:26

Pharma 130
article thumbnail

Pharma marketing: Getting personalized with Fingerpaint Group

Fierce Pharma

Marketers operating in every sector are seeking ways to offer personalized, high-quality experiences to their target audiences. | How much influence will AI exert over pharma marketing? Fingerpaint Group’s Paul Hagopian sits down with Fierce Pharma to discuss what has become a hotly contested topic.

Marketing 246
article thumbnail

Krystal's topical gene therapy gains steam, prompting analyst group to boost sales projection

Fierce Pharma

The drug launched after an FDA approval in May 2023.

Sales 295
article thumbnail

Another delay for Abeona's topical gene therapy pz-cel as FDA sends out a rejection

Fierce Pharma

Dating to a 2019 clinical hold of a phase 3 trial, getting its gene therapy ra | Dating to a 2019 clinical hold, getting its gene therapy pz-cel across the FDA finish line has been a challenge for troubled Abeona Therapeutics. Now the wait continues as the FDA has rejected the treatment due to CMC issues.

FDA 215